Menu
US
Literature - Publication Review

hESC-derived cardiomyocyte screening platform identifies novel inhibitors of SARS-Cov-2 viral entry

hesc-derived512

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19, the respiratory illness responsible for the COVID-19 pandemic. Studies have shown that patients infected with SARS-CoV-2 with cardiovascular comorbidities are more susceptible to severe infection and thus the case fatality rate in these patients rises. To further understand the pathology of SARS-CoV-2 in cardiomyocytes, a team of researchers from the University of Cambridge in the UK, have developed a screening platform using human embryonic stem cell-derived cardiomyocytes (hESC-CMs).

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

hESC-derived cardiomyocyte screening platform identifies novel inhibitors of SARS-Cov-2 viral entry

Download Literature - Publication Review